These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1332 related articles for article (PubMed ID: 33210302)

  • 1. COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
    Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol AK; Weiss A; Danahey K; Karrison TG; Edens CC; Bauer Ventura I; Pettit NN; Patel BK; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
    Clin Pharmacol Ther; 2021 Mar; 109(3):688-696. PubMed ID: 33210302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.
    Strohbehn GW; Heiss BL; Rouhani SJ; Trujillo JA; Yu J; Kacew AJ; Higgs EF; Bloodworth JC; Cabanov A; Wright RC; Koziol A; Weiss A; Danahey K; Karrison TG; Edens CC; Ventura IB; Pettit NN; Patel B; Pisano J; Strek ME; Gajewski TF; Ratain MJ; Reid PD
    medRxiv; 2020 Jul; ():. PubMed ID: 32743594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
    Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
    Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
    West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
    Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
    Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
    Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol.
    Piccirillo MC; Ascierto P; Atripaldi L; Cascella M; Costantini M; Dolci G; Facciolongo N; Fraganza F; Marata A; Massari M; Montesarchio V; Mussini C; Negri EA; Parrella R; Popoli P; Botti G; Arenare L; Chiodini P; Gallo C; Salvarani C; Perrone F
    Contemp Clin Trials; 2020 Nov; 98():106165. PubMed ID: 33031955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.
    Di Nisio M; Potere N; Candeloro M; Spacone A; Pieramati L; Ferrandu G; Rizzo G; La Vella M; Di Carlo S; Cibelli D; Parruti G; Levi M; Porreca E
    Eur J Intern Med; 2021 Jan; 83():34-38. PubMed ID: 33162299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
    Rosas IO; Bräu N; Waters M; Go RC; Hunter BD; Bhagani S; Skiest D; Aziz MS; Cooper N; Douglas IS; Savic S; Youngstein T; Del Sorbo L; Cubillo Gracian A; De La Zerda DJ; Ustianowski A; Bao M; Dimonaco S; Graham E; Matharu B; Spotswood H; Tsai L; Malhotra A
    N Engl J Med; 2021 Apr; 384(16):1503-1516. PubMed ID: 33631066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
    Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ;
    Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.